New monoclonal antibody to PCSK9 in Lipitor patients and possible 70% decrease in bad cholesterol ???

sailboat The winds of change AGAIN in cholesterol management—what is PCSK9 and how does it fit with Lipitor??

We’ve recently heard about challenges with increasing doses of medicines in the statin family and it appeared that science needed to bring us a new drug. WOW…the NEJM today has an original article about the effect of a new monoclonal antibody to PCSK9 on LDL cholesterol in patients on Lipitor.

PCSK9 binds to LDL receptors and makes them work for a shorter time, leading to increased LDL. An experimental antibody to PCSK9 appeared to avoid side effects that are possible with a larger statin dose AND lead to more than a 70% decrease in bad (LDL cholesterol for some patients)--AND no apparent increase in side effects. Definitely a rising star and a compound to watch !

 

dr rybacki kayak In the New England Journal of Medicine 3/22/12 !

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.